Vitek Lucille, Goronflot Thomas, Dutriaux Caroline, Deleuze Antoine, Le Corre Yannick, Duval-Modeste Anne-Bénédicte, Fresnard Cécile, Jeudy Géraldine, Lamoureux Anouck, Gaudy-Marqueste Caroline, Legoupil Delphine, Baroudjian Barouyr, L'Orphelin Jean-Matthieu, Peuvrel Lucie, Khammari Amir, Mortier Laurent, Quereux Gaëlle
Department of Dermatology, CHU de Nantes, Nantes, France.
Nantes University, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des Données, INSERM, CIC 1413, CHU Nantes, Nantes, France.
Acta Derm Venereol. 2024 Dec 12;104:adv41297. doi: 10.2340/actadv.v104.41297.
Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven survival benefit in a randomized clinical. Our purpose was to evaluate tebentafusp's real-life efficacy and tolerability for metastatic uveal melanoma. This retrospective study included patients from 14 French centres. Twenty-three patients were included. One-year survival was 66%; median progression-free survival was 5.7 months. Objective response rate was 23% and best overall response was complete remission for 4% of patients; partial remission for 18%, stable disease for 41%, and progressive disease for 36%. The most frequent adverse events were fever, chills, pruritus, and rash; 30% experienced severe adverse events. No death or treatment discontinuation was linked to adverse events. These data showed better overall survival with tebentafusp than that reported in historical cohorts.
转移性葡萄膜黑色素瘤是一种罕见疾病，预后较差。常规治疗方法尚未证实有效。替贝福单抗是一种靶向黑色素瘤细胞和T淋巴细胞的双特异性蛋白，是首个在随机临床试验中被证实具有生存获益的获批治疗药物。我们的目的是评估替贝福单抗对转移性葡萄膜黑色素瘤的实际疗效和耐受性。这项回顾性研究纳入了来自法国14个中心的患者。共纳入23例患者。1年生存率为66%；无进展生存期的中位数为5.7个月。客观缓解率为23%，最佳总体缓解情况为4%的患者完全缓解；18%的患者部分缓解，41%的患者病情稳定，36%的患者病情进展。最常见的不良事件为发热、寒战、瘙痒和皮疹；30%的患者发生严重不良事件。未出现与不良事件相关的死亡或治疗中断情况。这些数据表明，与历史队列报告相比，替贝福单抗治疗的总生存期更好。
